Creation of System Dynamics in an Uncertain and Complex Market: The Case of Korea’s Evolving Biopharmaceutical Industry

다국어 초록 (Multilingual Abstract)

This article explores the historical evolutionary process of the biopharmaceutical industry of Korea, and how intentional and unintentional policy interventions have triggered the creation of the industry’s system dynamics and paved the way for the generation of a few global leading products, including biosimilar, as well as next-generation therapeutics of gene and cell. The policies cover the simple technology transfer of API synthesis to overcome the endemic parasitic disease, new substance patent adoption and new drug development consortia, human resource development, various national initiatives influenced by the Human Genome Project, and venture promotion schemes. The scope and implementation tools under these policies have been aligned and refined to transform traditional fine chemical-based pharmaceuticals, to stimulate large companies’ participation and to create technologybased venture companies in the biopharma business of Korea.

참고문헌 (Reference)

1 Evaluate Pharma, "World preview 2017, Outlook to 2022"

2 Harrison, M., "War on two fronts: the fight against parasites in Korea and Vietnam" 61 (61): 401-423, 2017

3 GE Korea, "The Future of Work in Korea, A New Strategy for Growth"

4 Silverman, E., "The 5 most pressing ethical issues in biotech medicine" 1 (1): 41-46, 2004

5 Ministry of Science and ICT, "The 3rd Biotechnology Fostering Basic Plan" 2017

6 Jagschies, G., "Supply chain challenges in the biopharmaceutical industry: a case study following the 2011 Tsunami in Japan" 2014

7 Brill, A., "Steps to reducing barriers to biosimilars in the United States" Matrix Global Advisors 2018

8 Wong, J., "South Korean biotechnology - a rising industrial and scientific powerhouse" 22 : 42-47, 2004

9 Konde, V., "Secrets to developing a successful biotechnology industry: lessons from developing countries" 11 (11): 11-33, 2009

10 Otto, R., "Rapid Growth in Biopharma: Challenges and Opportunities"

11 Souad M Alsaqabi, "Praziquantel: A Review" OMICS Publishing Group 05 (05): 2014

12 Shah, N., "Pharmaceutical supply chains: key issues and strategies for optimization" 28 : 929-941, 2004

13 Depret, M., "Multiscale Clusters and Networks as the Foundations of Innovation Dynamics in the Biopharmaceutical Industry"

14 Euromonitor, "Leading Innovators: South Korea Becomes the Next Stop for Biotechnology"

15 Brendan, M.H., "Korea in the World: Promoting Mutual Understanding and Global Partnerships" Ministry of Foreign Affairs 2014

16 Business Korea, "Investors pour money into Korean biotech ventures"

17 Deloitte, "In the Face of Uncertainty: A Challenging Future for Biopharmaceutical Innovation"

18 Lücke, J., "How to plan a success-ful biopharma product rollout"

19 Kenney, M., "Global Change and East Asian Policy Initiatives" 2004

20 Falk, M.C., "Food biotechnology: benefits and concerns" 132 : 1384-1390, 2002

21 Annunziata, M., "EY life sciences sector update: Asia-Pacific and Japan" EYGM Limited 2016

22 Reich, M., "Dilemmas in Drug Development for Tropical Diseases: Experiences with Praziquantel" The World Bank 1997

23 Zika, E., "Consequences, Opportunities and Challenges of Modern Biotechnology for Europe" European Commission 2007

24 Alexander Schuhmacher, "Changing R&D models in research-based pharmaceutical companies" Springer Science and Business Media LLC 14 (14): 1-11, 2016

25 Ministry of Education, Science and Technology of Korea, "Biotechnology in Korea" Korea Research Institute of Bioscience and Biotechnology 2009

26 Rhee, S.K., "Biotechnology and Development: Challenges and Opportunities for Asia" Research and Information System for the Non-Aligned and Other Developing Countries 2003

27 Wong, J., "Betting on Biotech: Innovation and the Limits of Asia's Developmental State" Cornell University Press 2011

28 Dedrick, J., "Asia’s Computer Challenge: Threat or Oppor-tunity for the United States and the World?" Oxford University Press 1998

29 McKinsey, "Asia on the Move: Five Trends Shaping the Asia Biopharmaceutical Market"

30 Deloitte, "A New Future for R&D? Measuring the Return from Pharmaceutical Innovation 2017"